| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Elizabeth A. Garofalo is Director at ALEC and has filed Form 4s across 3 companies. Elizabeth A. Garofalo's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.0M at current prices.
Historically, Elizabeth A. Garofalo's trades have earned a below-average insider score of 46/100 across 3 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -5.2%.
The biggest single holding is ACAD (~$689K) as Director. The ACAD filings lean toward selling, a net 6,519 shares.
Elizabeth A. Garofalo has 28 Form 4 filings on record from September 2020 to June 2026, across 4 companies: Director at Alector (ALEC), 2021–2026; Director at Xenon Pharmaceuticals (XENE), 2021–2026; Director at ACADIA Pharmaceuticals (ACAD), 2020–2026, and 1 more.
The 50 reported transactions were 30 option or other derivative awards, 9 option exercises, 5 stock awards and 3 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 3 sales worth about $227K.
The largest open-market sale was 2,092 shares of XENE at an average $45.69 on March 8, 2024, about $96K. Twelve months later XENE was down 21%.
None of the 3 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | ACAD Acadia Pharmaceuticals Inc | Director | Sell | 1,600 | $25.98 | $41,560.48 | -5.9% | -3.3% | +12.6% | |
| Mar 5, 2025 | ACAD Acadia Pharmaceuticals Inc | Director | Sell | 4,919 | $18.23 | $89,673.37 | -21.8% | +21.6% | +23.9% | |
| Mar 8, 2024 | XENE Xenon Pharmaceuticals Inc. | Director | Sale+OE | 2,092 | $45.69 | $95,583.48 | - | -18.2% | -21.1% |